Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.
Donal P McLornanVittoria MalpassutiAnne Lippinkhof-KozijnVictoria PotterDietrich BeelenDonald BunjesHenrik SengeloevAleksandar RadujkovicJakob PasswegYves ChalandonNicolaus KrögerGerald G WulfJan-Erik JohanssonFabio CiceriMartin BornhäuserErnst HollerBlandine GuffroySonja MartinAndreas NeubauerMartin GramatskiMarie RobinSimona IacobelliPatrick HaydenJuan C Hernández BoludaTomasz CzerwIbrahim Yakoub-AghaPublished in: British journal of haematology (2020)
Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.
Keyphrases
- stem cell transplantation
- high dose
- end stage renal disease
- prognostic factors
- bone marrow
- chronic kidney disease
- ejection fraction
- newly diagnosed
- hematopoietic stem cell
- peritoneal dialysis
- palliative care
- low dose
- case report
- mesenchymal stem cells
- skeletal muscle
- stem cells
- big data
- metabolic syndrome
- cell death
- signaling pathway
- adipose tissue
- cell cycle arrest
- artificial intelligence
- weight loss